IGF-1 LR3

IGF-1 LR3 demonstrates significantly enhanced potency over native IGF-1 due to reduced binding protein affinity and extended half-life, promoting dose-dependent muscle growth.

Philippou & Barton (Growth Hormone & IGF Res.): Comprehensive review of IGF-1's role in muscle satellite cell activation, myoblast proliferation, and skeletal muscle regeneration.

Bowers et al.: Meta-analysis of epidemiological studies examining positive correlation between circulating IGF-1 levels and prostate, breast, and colorectal cancer risk.

A 2025 study found that a novel plant-based nerve conduit featuring controlled release of IGF-1 LR3 significantly improved axonal regeneration in a rat model of sciatic nerve injury. The conduit demonstrated performance comparable to autologous nerve grafts without inducing systemic toxicity.

A 2025 study found that a one-week infusion of IGF-1 LR3 did not improve growth or insulin secretion in growth-restricted fetal sheep. However, the treatment demonstrated a reduction in circulating amino acids, suggesting increased amino acid utilization.

A 2025 study found that intranasal LR3-IGF-1 promoted amyloid plaque remodeling and reduced low molecular weight Aβ oligomers in the cerebral cortex of an Alzheimer's mouse model. However, the treatment failed to preserve cognitive function or memory in the mice.

A 2024 study demonstrated a simplified, validated chromatographic-mass spectrometric method for efficiently extracting and detecting prohibited peptides, including insulins and GHRHs, in doping control urine samples. The approach successfully met World Anti-Doping Agency requirements and was verified using authentic post-administration samples.

A 2023 study found that an IGF1 analog mitigated age-related loss of gastric pacemaker cells in mice by activating ERK1/2 signaling. This preservation demonstrated improved gastric compliance, increased food intake, and prevented impaired body weight gain in the animal model.

In a 2023 study, researchers demonstrated that high levels of bioactive human IGF-1 and its analog LR3 IGF-1 can be successfully produced in a Pichia pastoris expression system by fusing them with xylanase. The purified recombinant proteins exhibited excellent cell proliferation bioactivity comparable to standard IGF-1.

A 2023 study demonstrated that acute IGF-1 LR3 infusion in fetal sheep suppressed in vivo glucose-stimulated insulin secretion. However, researchers found that isolated islets retained the ability to recover insulin secretion in vitro, indicating beta-cells can overcome acute suppression.